Using brain stimulation to improve cognitive function in stroke patients
The Second Hospital of Dalian Medical University
This study is testing whether a brain stimulation treatment can help improve thinking skills in stroke patients while they receive regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | The Second Affiliated Hospital of Dalian Medical University Academic / other |
| Locations | 2 sites (Dalian, Liaoning and 1 other locations) |
| Trial ID | NCT06386614 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of transcranial direct current stimulation (tDCS) on cognitive impairment in stroke patients. Participants will receive standard treatment alongside tDCS, and their cognitive function and plasma levels of brain-derived neurotrophic factor (BDNF) will be assessed. The study aims to establish a correlation between BDNF levels and cognitive function in these patients, potentially leading to new therapeutic strategies for post-stroke cognitive impairment.
Who should consider this trial
Good fit: Ideal candidates are stroke patients aged 40-80 with documented cognitive impairment and specific MoCA or MMSE scores.
Not a fit: Patients with severe aphasia or those unable to cooperate with evaluations and treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance cognitive function in stroke patients, improving their quality of life.
How similar studies have performed: Other studies have shown promising results using tDCS for cognitive enhancement, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1)Stroke patients with CT or MRI imaging evidence, among which ischemic stroke met the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018, and cerebral hemorrhage diseases met the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Cerebral hemorrhage 2019; (2) There are symptoms related to cognitive dysfunction; Cognitive dysfunction was assessed by rehabilitation physicians. According to the MoCA evaluation standard,MoCA score ≤26 points; according to the MMSE evaluation standard, illiteracy score ≤17 points; primary school education level ≤20 points; secondary school education (including secondary school) level ≤22 points; college education (including junior college) level ≤23 points; (3)Age range 40-80 years old; (4) no obvious aphasia, speech expression and attention can cooperate with the completion of evaluation and treatment; (5)The patient or the patient's family members read and agree to sign the informed consent. Exclusion Criteria: * (1) Patients with severe diseases, such as malignant arrhythmia, acute myocardial infarction and acute heart failure, who cannot tolerate rehabilitation treatment; (2) Patients with untreated intracranial aneurysms, severe epilepsy, and intracranial metals who cannot receive tDCS treatment; (3) Non-PSCI patients with cognitive impairment, including patients with cognitive impairment left over from previous stroke and other organ disorders.
Where this trial is running
Dalian, Liaoning and 1 other locations
- Department of Rehabilitation Medicine, the Second Hospital of Dalian Medical University — Dalian, Liaoning, China (Completed)
- Lily — Dalian, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Yang Tu
- Email: 715700399@qq.com
- Phone: 18875214238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.